Trial Profile

A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MT-5625 (Primary) ; RIX 4414
Indications Rotavirus infections
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation; Tanabe Pharma America

31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
31 Oct 2025 According to Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma America is now called Tanabe Pharma America
25 Aug 2021 Results published in the Vaccine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com